Phcog.Net logo

BROWSE ALL JOURNALS

    SEE ALL 6 JOURNALS
    Article

    Unveiling the Therapeutic Potential of Bauhinia racemosa High-Throughput Screening for Hypoxia-Induced Receptor Inhibitors in Sickle Cell Disease (SCD)

    Mohammad Nadeem Khan1★, Mahak Bhandari2, Sanjay Vyas3, Shushil Upadhayay4, Praveen Chandra Dubey5★ Corresponding author

    1. 1Department of Pharmacology (Clinical Pharmacology), Sri Aurobindo Medical College and PG Institute, Sanwer Road, Indore, Madhya Pradesh, INDIA.
    2. 2Department of Surgery, Sri Aurobindo Medical College & PG Institute, Sri Aurobindo University, Ujjain-Indore State Highway, Indore, Madhya Pradesh, INDIA.
    3. 3Department of Microbiology and Horticulture, Government Holker Science College, Indore, Madhya Pradesh, INDIA.
    4. 4Department of Interrogative Medicine, Project-Co-Ordinator CSR/CER/Activity Traditional Healer, Sri Aurobindo University, Ujjain-Indore State Highway, Indore, Madhya Pradesh, INDIA.
    5. 5Department of Forest, Chairman SEAC-Committee, Bhopal, Ex-PCCF, Madhya Pradesh, INDIA.

    CORRESPONDENCE

    Mohammad Nadeem Khan

    Department of Pharmacology (Clinical Pharmacology), Sri Aurobindo Medical College and PG Institute, Sanwer Road, Indore, Madhya Pradesh, INDIA.

    sahani.nadeem35@gmail.com

    Received: 27-12-2025; Revised: 11-02-2026; Accepted: 09-04-2026.

    Volume 15, Issue 2 · pp. 66–77 · PUBLISHED 2025 · DOI: 10.5530/fra.2025.2.9

    View on Free Rad. Antiox. original site ↗

    ABSTRACT

    Background: Sickle Cell Disease (SCD) is a major genetic disorder with significant morbidity and mortality, particularly among tribal populations in Madhya Pradesh, India. The prevalence of sickle cell hemoglobin among these communities ranges from 10-33%, with about 0.7% suffering from SCD. Hypoxia plays a central role in the pathophysiology of SCD, and the inhibition of Hypoxia-Inducible Factor (HIF) Prolyl Hydroxylase (PHD) proteins has emerged as a promising therapeutic strategy. Aim and Objectives: This study investigates Bauhinia racemosa's ethnomedicinal uses in Central India, screens its phytochemicals for inhibitory activity against HIF-PHD proteins, and evaluates their binding affinity, stability, and interactions through in silico docking, comparing results with standard inhibitors like Desidustat. Materials and Methods: Ethnobotanical fieldwork in Alirajpur, Jhabua, and Dhar identified medicinal uses of Bauhinia racemosa. Twelve bioactive compounds were screened and evaluated via in silico docking, RMSD analysis, and receptor-ligand interaction studies, comparing them with known HIF inhibitors. Results: Out of the twelve screened phytochemicals, compounds such as Quercetin, Stigmasterol, and 3-O-Methylquercetin exhibited high binding affinity scores ranging from -10.7 to -12.9 kcal/ mol, surpassing the standard inhibitors like Desidustat (-9.7 kcal/mol). RMSD analysis showed these phytochemicals formed stable complexes with the HIF-PHD receptor. Strong hydrogen bonding and hydrophobic interactions further enhanced the receptor-ligand binding stability, indicating a high therapeutic potential. Conclusion: Bauhinia racemosa phytochemicals exhibit strong inhibitory potential against HIF-PHD proteins, demonstrating superior binding affinity and stability compared to standard inhibitors, offering promising therapeutic prospects for hypoxia-related disorders.

    KEYWORDS

    Open in new tab

    REFERENCES

    As published

    Showing references and in-text citations exactly as published.

      Cite this article

      SELECT FORMAT

      Khan, M. N., Bhandari, M., Vyas, S., Upadhayay, S., & Dubey, P. C. (2025). Unveiling the Therapeutic Potential of Bauhinia racemosa High-Throughput Screening for Hypoxia-Induced Receptor Inhibitors in Sickle Cell Disease (SCD). Free Radicals and Antioxidants, 15(2), 66–77. https://doi.org/10.5530/fra.2025.2.9